Journal
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
Volume 8, Issue 1, Pages 160-174Publisher
WILEY
DOI: 10.1002/wnan.1356
Keywords
-
Funding
- U.S. National Institutes of Health, National Eye Institute [R21 EY024059-ZH]
- Oklahoma Center for the Advancement of Science and Technology
- Knights Templar Eye Foundation
- Carolina Center of Cancer Nanotechnology Excellence
- North Carolina Translational and Clinical Sciences
- Fight for Sight
- Research to Prevent Blindness
Ask authors/readers for more resources
Ophthalmic gene therapy is an intellectual and intentional manipulation of desired gene expression into the specific cells of an eye for the treatment of ophthalmic (ocular) genetic dystrophies and pathological conditions. Exogenous nucleic acids such as DNA, small interfering RNA, micro RNA, and so on, are used for the purpose of managing expression of the desired therapeutic proteins in ocular tissues. The delivery of unprotected nucleic acids into the cells is limited because of exogenous and endogenous degradation modalities. Nanotechnology, a promising and sophisticated cutting edge tool, works as a protective shelter for these therapeutic nucleic acids. They can be safely delivered to the required cells in order to modulate anticipated protein expression. To this end, nanotechnology is seen as a potential and promising strategy in the field of ocular gene delivery. This review focused on current nanotechnology modalities and other promising nonviral strategies being used to deliver therapeutic genes in order to treat various devastating ocular diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available